NCT05104463View on ClinicalTrials.gov

A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 11, 2022

Primary Completion Date

December 20, 2023

Study Completion Date

February 1, 2024

Conditions
Mild Cognitive ImpairmentDementia
Interventions
DRUG

CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107

CST-2032 and matching placebo white tablets, CST-107 and matching placebo yellow tablets

Trial Locations (15)

8011

CuraSen Investigational Site, Christchurch

10003

CuraSen Investigational Site, New York

32159

CuraSen Investigational Site, Lady Lake

32792

CuraSen Investigational Site, Winter Park

33176

CuraSen Investigational Site, Miami

33486

CuraSen Investigational Site, Boca Raton

34205

CuraSen Investigational Site, Bradenton

34652

CuraSen Investigational Site, New Port Richey

45242

CuraSen Investigational Site, Cincinnati

77074

CuraSen Investigational Site, Houston

77477

CuraSen Investigational Site, Stafford

78681

CuraSen Investigational Site, Round Rock

84102

CuraSen Investigational Site, Salt Lake City

85258

CuraSen Investigational Site, Scottsdale

94549

CuraSen Investigational Site, Lafayette

Sponsors
All Listed Sponsors
lead

CuraSen Therapeutics, Inc.

INDUSTRY

NCT05104463 - A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease | Biotech Hunter | Biotech Hunter